Estrella Immunopharma Warrant
ESLAW
10 hedge funds and large institutions have $2.69M invested in Estrella Immunopharma Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
1,743% more capital inflows, than outflows
Capital inflows: $36.9K | Capital outflows: $2K
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SONA Asset Management (US)
New York
|
-$2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2 |
ESLAW Hedge Fund Activity: Q1 2022 in Review
10 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q1 2022, worth a combined $2.69M — down 42% from $4.65M a quarter earlier.
Fund positioning in ESLAW was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was SONA Asset Management (US), exiting entirely with an estimated $2K sold.
- 10 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $2.69M of Estrella Immunopharma Warrant stock for Q1 2022, down 42% quarter-over-quarter.
- 1 fund opened new Estrella Immunopharma Warrant positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Estrella Immunopharma Warrant seller in Q1 2022 was SONA Asset Management (US), an estimated $2K sold.
Based on aggregated 13F filings for Q1 2022.